Primary immune thrombocytopenia(ITP)is an immune-mediated bleeding disorder characterized by de-creased platelet counts and an increased risk of bleeding.Traditional ITP treatment strategies work through mitigating immune-mediated platelet destruction,such as glucocorticosteroids,immunoglobulins,immunomodulatory agents,or splenec-tomy.Although these strategies are usually effective,many patients have poor responsiveness to these therapies and their use is limited by treatment-related side effects and contraindications.In recent years,thrombopoietin receptor agonists(TPO-RA),by promoting platelet production,has become a new choice for the treatment of ITP.This article focuses on the pro-gress and safety characteristics of TPO-RA,aiming to provide reference for the research and clinical use of TPO-RA.
关键词
免疫性血小板减少症/血小板生成素受体激动剂/安全性特征/研发进展
Key words
Primary immune thrombocytopenia/Thrombopoietin receptor agonists/Safety characteristics/Research and development progress
维普
万方数据